10:33 EDT FDA approves Corcept Therapeutics (CORT)’ Lifyorli for certain cancers
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics trading halted, volatility trading pause
- Corcept Therapeutics management to meet with Piper Sandler
- Corcept Therapeutics director buys $3.3M in common stock
- Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements
- Corcept Therapeutics Balances Growth With Rising Risks